Ate-Bev Early Response Prediction Model in Advanced HCC

Recruiting now

Conditions studied: Hepatocellular Carcinoma, Atezolizumab-bevacizumab, Response Evaluation

In brief

The prognosis of hepatocellular carcinoma is poor compared to other carcinomas. Many drugs have recently been developed, and recently, atezolizumab-bevacizumab treatment was superior to sorafenib, the conventional treatment for advanced hepatocellular carcinoma. However, there is no information on the evaluation on the evaluation of treatment response for atezolizumab-bevacizumab combination therapy compared to atezolizumab alone or bevacizumab alone. Therefore, this study aimed to create a predictive model that can detect treatment response at an early stage.

Key facts

Study ID

NCT05763277

Run by

Seoul National University Hospital

People needed

170

Starts

2022-07-22

Expected to finish

2026-12-31

Last updated by the study team

2025-05-15

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patients who were diagnosed with advanced hepatocellular carcinoma and who were scheduled to receive atezolizumab-bevacizumab as the first-line therapy
• Patients willing to participate in this study

You may not qualify if…

• Individuals with a history of severe contrast allergy
• Individuals with severe comorbidities (according to the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction.)

Where it is running

• Seoul National University Hospital — Seoul, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.